Equities analysts expect that Pfizer Inc. (NYSE:PFE) will post earnings of $0.75 per share for the current quarter, Zacks reports. Three analysts have made estimates for Pfizer’s earnings, with estimates ranging from $0.72 to $0.78. Pfizer posted earnings per share of $0.67 in the same quarter last year, which indicates a positive year-over-year growth rate of 11.9%. The firm is expected to announce its next earnings report on Tuesday, October 30th.

According to Zacks, analysts expect that Pfizer will report full year earnings of $2.99 per share for the current fiscal year, with EPS estimates ranging from $2.95 to $3.03. For the next fiscal year, analysts forecast that the firm will post earnings of $3.07 per share, with EPS estimates ranging from $2.99 to $3.14. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Pfizer.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.07. The firm had revenue of $13.47 billion for the quarter, compared to the consensus estimate of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.67 EPS.

A number of research analysts recently issued reports on PFE shares. Credit Suisse Group boosted their target price on shares of Pfizer from $39.00 to $40.00 and gave the company a “neutral” rating in a research report on Wednesday, August 1st. Morgan Stanley set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, August 29th. Bank of America boosted their target price on shares of Pfizer from $42.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, August 1st. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, July 15th. Finally, JPMorgan Chase & Co. reiterated a “$37.66” rating on shares of Pfizer in a research report on Wednesday, July 18th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the stock. Pfizer presently has a consensus rating of “Hold” and a consensus target price of $41.89.

Pfizer stock opened at $42.20 on Wednesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.91 and a current ratio of 1.16. Pfizer has a 12-month low of $33.20 and a 12-month high of $42.77. The firm has a market cap of $248.71 billion, a P/E ratio of 14.56, a P/E/G ratio of 2.01 and a beta of 0.96.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 4th. Shareholders of record on Friday, August 3rd were paid a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, August 2nd. This represents a $1.36 dividend on an annualized basis and a yield of 3.22%. Pfizer’s dividend payout ratio (DPR) is presently 51.32%.

In other Pfizer news, insider Laurie J. Olson sold 10,214 shares of the business’s stock in a transaction on Monday, August 13th. The shares were sold at an average price of $41.00, for a total transaction of $418,774.00. Following the completion of the sale, the insider now owns 72,672 shares in the company, valued at approximately $2,979,552. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 25,642 shares of the business’s stock in a transaction on Friday, August 3rd. The shares were sold at an average price of $39.51, for a total transaction of $1,013,115.42. Following the sale, the insider now owns 127,954 shares of the company’s stock, valued at approximately $5,055,462.54. The disclosure for this sale can be found here. Insiders have sold a total of 761,230 shares of company stock valued at $29,054,690 in the last 90 days. 0.06% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the business. Ballew Advisors Inc bought a new stake in shares of Pfizer in the 1st quarter worth $102,000. Earnest Partners LLC bought a new stake in shares of Pfizer in the 4th quarter worth $105,000. Woodard & Co. Asset Management Group Inc. ADV purchased a new position in shares of Pfizer in the 4th quarter worth about $118,000. Fort L.P. purchased a new position in shares of Pfizer in the 2nd quarter worth about $121,000. Finally, Delpha Capital Management LLC purchased a new position in shares of Pfizer in the 4th quarter worth about $126,000. Institutional investors and hedge funds own 69.12% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Story: Trading Penny Stocks

Get a free copy of the Zacks research report on Pfizer (PFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.